{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:57:35Z","timestamp":1782741455803,"version":"3.54.5"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40123-026-01407-z","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:38:08Z","timestamp":1780576688000},"page":"2187-2211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update on the Management of ABCA4 Retinopathy (Stargardt Disease)"],"prefix":"10.1007","volume":"15","author":[{"given":"Deepika C.","family":"Parameswarappa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanashree","family":"Ratra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goura","family":"Chattannavar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6453-5851","authenticated-orcid":false,"given":"Srikanta Kumar","family":"Padhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"3","key":"1407_CR1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/ng0397-236","volume":"15","author":"R Allikmets","year":"1997","unstructured":"Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A, Chidambaram A, et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet. 1997;15(3):236\u201346. https:\/\/doi.org\/10.1038\/ng0397-236. (Erratum in: Nat Genet. 1997 Sep;17(1):122. doi: 10.1038\/ng0997-122a).","journal-title":"Nat Genet"},{"issue":"10","key":"1407_CR2","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.4103\/IJO.IJO_3290_22","volume":"71","author":"AV Das","year":"2023","unstructured":"Das AV, Venugopal R, Takkar B, Sharma S, Balakrishnan N, Narayanan R, et al. Clinical profile and demographic distribution of Stargardt disease phenotypes: an electronic medical record-driven big data analytics from a multitier eye care network. Indian J Ophthalmol. 2023;71(10):3407\u201311. https:\/\/doi.org\/10.4103\/IJO.IJO_3290_22.","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"1407_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-024-01272-y","volume":"14","author":"YA Zaydon","year":"2024","unstructured":"Zaydon YA, Tsang SH. The ABCs of Stargardt disease: the latest advances in precision medicine. Cell Biosci. 2024;14(1):98. https:\/\/doi.org\/10.1186\/s13578-024-01272-y.","journal-title":"Cell Biosci"},{"issue":"3","key":"1407_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/77004","volume":"25","author":"LL Molday","year":"2000","unstructured":"Molday LL, Rabin AR, Molday RS. ABCR expression in foveal cone photoreceptors and its role in Stargardt macular dystrophy. Nat Genet. 2000;25(3):257\u20138.","journal-title":"Nat Genet"},{"issue":"1","key":"1407_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/ng0997-15","volume":"17","author":"H Sun","year":"1997","unstructured":"Sun H, Nathans J. Stargardt\u2019s ABCR is localized to the disc membrane of retinal rod outer segments. Nat Genet. 1997;17(1):15\u20136.","journal-title":"Nat Genet"},{"key":"1407_CR6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/ncomms1927","volume":"3","author":"F Quazi","year":"2012","unstructured":"Quazi F, Lenevich S, Molday RS. ABCA4 is an N-retinylidene-phosphatidylethanolamine and phosphatidylethanolamine importer. Nat Commun. 2012;3:925. https:\/\/doi.org\/10.1038\/ncomms1927.","journal-title":"Nat Commun"},{"issue":"48","key":"1407_CR7","doi-asserted-by":"publisher","first-page":"34414","DOI":"10.1074\/jbc.M113.508812","volume":"288","author":"F Quazi","year":"2013","unstructured":"Quazi F, Molday RS. Differential phospholipid substrates and directional transport by ATP-binding cassette proteins ABCA1, ABCA7, and ABCA4 and disease-causing mutants. J Biol Chem. 2013;288(48):34414\u201326.","journal-title":"J Biol Chem"},{"issue":"2","key":"1407_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/79994","volume":"26","author":"H Sun","year":"2000","unstructured":"Sun H, Smallwood PM, Nathans J. Biochemical defects in ABCR protein variants associated with human retinopathies. Nat Genet. 2000;26(2):242\u20136.","journal-title":"Nat Genet"},{"issue":"6","key":"1407_CR9","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1074\/jbc.M806580200","volume":"284","author":"M Zhong","year":"2009","unstructured":"Zhong M, Molday LL, Molday RS. Role of the C terminus of the photoreceptor ABCA4 transporter in protein folding, function, and retinal degenerative diseases. J Biol Chem. 2009;284(6):3640\u20139.","journal-title":"J Biol Chem"},{"issue":"16","key":"1407_CR10","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1073\/pnas.0308302101","volume":"101","author":"RA Radu","year":"2004","unstructured":"Radu RA, Mata NL, Bagla A, Travis GH. Light exposure stimulates formation of A2E oxiranes in a mouse model of Stargardt\u2019s macular degeneration. Proc Natl Acad Sci USA. 2004;101(16):5928\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"1407_CR11","first-page":"1981","volume":"41","author":"JR Sparrow","year":"2000","unstructured":"Sparrow JR, Nakanishi K, Parish CA. The lipofuscin fluorophore A2E mediates blue light\u2013induced damage to retinal pigmented epithelial cells. Investig Ophthalmol Vis Sci. 2000;41(7):1981\u20139.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"1407_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.exer.2005.01.007","volume":"80","author":"JR Sparrow","year":"2005","unstructured":"Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res. 2005;80(5):595\u2013606.","journal-title":"Exp Eye Res"},{"issue":"3","key":"1407_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13030362","volume":"13","author":"R Salceda","year":"2024","unstructured":"Salceda R. Light pollution and oxidative stress: effects on retina and human health. Antioxidants. 2024;13(3):362. https:\/\/doi.org\/10.3390\/antiox13030362.","journal-title":"Antioxidants"},{"issue":"12","key":"1407_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12122111","volume":"12","author":"MB R\u00f3\u017canowska","year":"2023","unstructured":"R\u00f3\u017canowska MB. Lipofuscin, its origin, properties, and contribution to retinal fluorescence as a potential biomarker of oxidative damage to the retina. Antioxidants. 2023;12(12):2111. https:\/\/doi.org\/10.3390\/antiox12122111.","journal-title":"Antioxidants"},{"issue":"5","key":"1407_CR15","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.ajo.2015.02.004","volume":"159","author":"MM Teussink","year":"2015","unstructured":"Teussink MM, Lee MD, Smith RT, van Huet RA, Klaver CC, Klevering BJ, et al. The effect of light deprivation in patients with Stargardt disease. Am J Ophthalmol. 2015;159(5):964-72.e2. https:\/\/doi.org\/10.1016\/j.ajo.2015.02.004. (Epub 2015 Feb 11).","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1407_CR16","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1167\/iovs.14-13867","volume":"55","author":"L Wu","year":"2014","unstructured":"Wu L, Ueda K, Nagasaki T, Sparrow JR. Light damage in Abca4 and Rpe65rd12 mice. Investig Ophthalmol Vis Sci. 2014;55(3):1910\u20138. https:\/\/doi.org\/10.1167\/iovs.14-13867.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"9","key":"1407_CR17","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.14.9.26","volume":"14","author":"AC Britten-Jones","year":"2025","unstructured":"Britten-Jones AC, Al-Khuzaei S, Rizzi M, Crossland MD, Rozanowska MB, Mendes BS, et al. Stargardt\u2019s Connected Research Network Inaugural Meeting: landscape review and horizon scanning of Stargardt disease. Transl Vis Sci Technol. 2025;14(9):26. https:\/\/doi.org\/10.1167\/tvst.14.9.26.","journal-title":"Transl Vis Sci Technol"},{"issue":"9","key":"1407_CR18","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1167\/iovs.07-1470","volume":"49","author":"RA Radu","year":"2008","unstructured":"Radu RA, Yuan Q, Hu J, Peng JH, Lloyd M, Nusinowitz S, et al. Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following Vitamin A supplementation. Invest Ophthalmol Vis Sci. 2008;49(9):3821\u20139. https:\/\/doi.org\/10.1167\/iovs.07-1470. (Epub 2008 May 30).","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"19","key":"1407_CR19","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/gt.2008.78","volume":"15","author":"J Kong","year":"2008","unstructured":"Kong J, Kim SR, Binley K, Pata I, Doi K, Mannik J, et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther. 2008;15(19):1311\u201320. https:\/\/doi.org\/10.1038\/gt.2008.78. (Epub 2008 May 8).","journal-title":"Gene Ther"},{"issue":"5","key":"1407_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13816810.2018.1488174","volume":"39","author":"CA Federspiel","year":"2018","unstructured":"Federspiel CA, Bertelsen M, Kessel L. Vitamin A in Stargardt disease\u2014an evidence-based update. Ophthalmic Genet. 2018;39(5):555\u20139. https:\/\/doi.org\/10.1080\/13816810.2018.1488174.","journal-title":"Ophthalmic Genet"},{"key":"1407_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-016-0187-3","volume":"16","author":"F Sofi","year":"2016","unstructured":"Sofi F, Sodi A, Franco F, Murro V, Biagini D, Miele A, et al. Dietary profile of patients with Stargardt\u2019s disease and retinitis pigmentosa: is there a role for a nutritional approach? BMC Ophthalmol. 2016;16:13. https:\/\/doi.org\/10.1186\/s12886-016-0187-3.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"1407_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/vision9010016","volume":"9","author":"K Saigal","year":"2025","unstructured":"Saigal K, Salama JE, Pardo AA, Lopez SE, Gregori NZ. Modifiable lifestyle risk factors and strategies for slowing the progression of age-related macular degeneration. Vision. 2025;9(1):16. https:\/\/doi.org\/10.3390\/vision9010016.","journal-title":"Vision"},{"issue":"4","key":"1407_CR23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/cxo.12867","volume":"102","author":"K Das","year":"2019","unstructured":"Das K, Gopalakrishnan S, Dalan D, Velu S, Ratra V, Ratra D. Factors influencing the choice of low-vision devices for visual rehabilitation in Stargardt disease. Clin Exp Optom. 2019;102(4):426\u201333. https:\/\/doi.org\/10.1111\/cxo.12867.","journal-title":"Clin Exp Optom"},{"issue":"2","key":"1407_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/cxo.12834","volume":"102","author":"D Ratra","year":"2019","unstructured":"Ratra D, Gopalakrishnan S, Dalan D, Ratra V, Damkondwar D, Laxmi G. Visual rehabilitation using microperimetric acoustic biofeedback training in individuals with central scotoma. Clin Exp Optom. 2019;102(2):172\u20139. https:\/\/doi.org\/10.1111\/cxo.12834.","journal-title":"Clin Exp Optom"},{"issue":"14","key":"1407_CR25","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.3390\/ijms26147006","volume":"26","author":"K Dayma","year":"2025","unstructured":"Dayma K, Rajanala K, Upadhyay A. Stargardt\u2019s disease: molecular pathogenesis and current therapeutic landscape. Int J Mol Sci. 2025;26(14):7006. https:\/\/doi.org\/10.3390\/ijms26147006.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1407_CR26","first-page":"2685","volume":"57","author":"HP Scholl","year":"2016","unstructured":"Scholl HP, Shah SM, Kay CN, Tsang SH, Stapien KE, Bernstein PS, et al. TEASE: a phase 2 clinical trial assessing the tolerability and effects of oral once-a-day ALK-001 on Stargardt disease. Investig Ophthalmol Vis Sci. 2016;57(12):2685.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"7","key":"1407_CR27","first-page":"38","volume":"63","author":"HP Scholl","year":"2022","unstructured":"Scholl HP, DeBartolomeo G, Washington I, Saad L. ALK-001 (C20-D3-Vitamin A) slows the growth of atrophic lesions in ABCA4-related Stargardt disease: results of a phase 2 placebo-controlled clinical trial (TEASE study). Invest Ophthalmol Vis Sci. 2022;63(7):38.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1407_CR28","first-page":"3310","volume":"65","author":"MB Gorin","year":"2024","unstructured":"Gorin MB, Saad L, DeBartolomeo G, Washington I, Scholl HP, Mathiias MT, et al. Gildeuretinol arrested Stargardt disease, the TEASE-3 study. Investig Ophthalmol Vis Sci. 2024;65(7):3310.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"226","key":"1407_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113856","volume":"15","author":"N Kim","year":"2021","unstructured":"Kim N, Priefer R. Retinol binding protein 4 antagonists and protein synthesis inhibitors: potential for therapeutic development. Eur J Med Chem. 2021;15(226):113856. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113856.","journal-title":"Eur J Med Chem"},{"issue":"7","key":"1407_CR30","first-page":"3518","volume":"63","author":"JR Grigg","year":"2022","unstructured":"Grigg JR, Chen FK, Chen TC, Jamieson RV, Mata NL, Liao W. A phase 1b\/2 study of the safety and tolerability of tinlarebant in adolescent STGD1 subjects. Investig Ophthalmol Vis Sci. 2022;63(7):3518\u20133518.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"7","key":"1407_CR31","first-page":"1026","volume":"65","author":"JR Grigg","year":"2024","unstructured":"Grigg JR, Chen F, Chen TC, Jamieson RV, Scholl HP, Michaelides M, et al. Safety, tolerability, and efficacy of tinlarebant from the 24-month phase 2 study in adolescent patients affected by Stargardt disease. Investig Ophthalmol Vis Sci. 2024;65(7):1026\u20131026.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1407_CR32","unstructured":"https:\/\/investors.belitebio.com\/news-releases\/news-release-details\/belite-bio-announces-completion-dragon-2-year-phase-3-trial-oral."},{"issue":"3","key":"1407_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/bjophthalmol-2020-317712","volume":"106","author":"R Kubota","year":"2022","unstructured":"Kubota R, Birch DG, Gregory JK, Koester JM. Randomised study evaluating the pharmacodynamics of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease. Br J Ophthalmol. 2022;106(3):403\u20138. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317712. (Epub 2020 Nov 19).","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"1407_CR34","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1167\/iovs.05-0820","volume":"46","author":"RA Radu","year":"2005","unstructured":"Radu RA, Han Y, Bui TV, Nusinowitz S, Bok D, Lichter J, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Investig Ophthalmol Vis Sci. 2005;46(12):4393\u2013401.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"11","key":"1407_CR35","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1016\/j.stemcr.2022.10.001","volume":"17","author":"M Farnoodian","year":"2022","unstructured":"Farnoodian M, Bose D, Khristov V, et al. Cell-autonomous lipid-handling defects in Stargardt iPSC-derived retinal pigment epithelium cells. Stem Cell Rep. 2022;17(11):2438\u201350. https:\/\/doi.org\/10.1016\/j.stemcr.2022.10.001.","journal-title":"Stem Cell Rep"},{"issue":"8","key":"1407_CR36","first-page":"476","volume":"64","author":"M Farnoodian","year":"2023","unstructured":"Farnoodian M, Barone F, Boyle M, et al. Metformin attenuates the hallmarks of Stargardt disease. Investig Ophthalmol Vis Sci. 2023;64(8):476.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"21","key":"1407_CR37","doi-asserted-by":"publisher","first-page":"18593","DOI":"10.1074\/jbc.M110.191866","volume":"286","author":"RA Radu","year":"2011","unstructured":"Radu RA, Hu J, Yuan Q, Welch DL, Makshanoff J, Lloyd M, et al. Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. J Biol Chem. 2011;286(21):18593\u2013601. https:\/\/doi.org\/10.1074\/jbc.M110.191866.","journal-title":"J Biol Chem"},{"issue":"4","key":"1407_CR38","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","volume":"128","author":"GJ Jaffe","year":"2021","unstructured":"Jaffe GJ, Westby K, Csaky KG, Mon\u00e9s J, Pearlman JA, Patel SS, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial. Ophthalmology. 2021;128(4):576\u201386. https:\/\/doi.org\/10.1016\/j.ophtha.2020.08.027.","journal-title":"Ophthalmology"},{"issue":"7","key":"1407_CR39","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1074\/jbc.M111.275438","volume":"287","author":"J Gautherot","year":"2012","unstructured":"Gautherot J, Durand-Schneider AM, Delautier D, Delaunay JL, Rada A, Gabillet J, et al. Effects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1\/ABCB4. J Biol Chem. 2012;287(7):5070\u20138. https:\/\/doi.org\/10.1074\/jbc.M111.275438. (Epub 2011 Dec 19).","journal-title":"J Biol Chem"},{"issue":"100","key":"1407_CR40","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.ddtec.2014.03.009","volume":"12","author":"EL Rudashevskaya","year":"2014","unstructured":"Rudashevskaya EL, Stockner T, Trauner M, Freissmuth M, Chiba P. Pharmacological correction of misfolding of ABC proteins. Drug Discov Today Technol. 2014;12(100):e87-94. https:\/\/doi.org\/10.1016\/j.ddtec.2014.03.009.","journal-title":"Drug Discov Today Technol"},{"issue":"32","key":"1407_CR41","doi-asserted-by":"publisher","first-page":"19743","DOI":"10.1074\/jbc.M115.647685","volume":"290","author":"I Sabirzhanova","year":"2015","unstructured":"Sabirzhanova I, Lopes Pacheco M, Rapino D, Grover R, Handa JT, Guggino WB, et al. Rescuing trafficking mutants of the ATP-binding cassette protein, ABCA4, with small molecule correctors as a treatment for Stargardt eye disease. J Biol Chem. 2015;290(32):19743\u201355. https:\/\/doi.org\/10.1074\/jbc.M115.647685. (Epub 2015 Jun 19).","journal-title":"J Biol Chem"},{"issue":"2","key":"1407_CR42","doi-asserted-by":"publisher","first-page":"400","DOI":"10.33594\/000000146","volume":"53","author":"Q Liu","year":"2019","unstructured":"Liu Q, Sabirzhanova I, Bergbower EAS, Yanda M, Guggino WG, Cebotaru L. The CFTR corrector, VX-809 (Lumacaftor), rescues ABCA4 trafficking mutants: a potential treatment for Stargardt disease. Cell Physiol Biochem. 2019;53(2):400\u201312. https:\/\/doi.org\/10.33594\/000000146.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"1407_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-51203-7","volume":"14","author":"M Kaltak","year":"2024","unstructured":"Kaltak M, de Bruijn P, van Leeuwen W, Platenburg G, Cremers FPM, Collin RWJ, et al. QR-1011 restores defective ABCA4 splicing caused by multiple severe ABCA4 variants underlying Stargardt disease. Sci Rep. 2024;14(1):684. https:\/\/doi.org\/10.1038\/s41598-024-51203-7.","journal-title":"Sci Rep"},{"issue":"8","key":"1407_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084521","volume":"25","author":"D Piccolo","year":"2024","unstructured":"Piccolo D, Zarouchlioti C, Bellingham J, Guarascio R, Ziaka K, Molday RS, et al. A proximity complementation assay to identify small molecules that enhance the traffic of ABCA4 misfolding variants. Int J Mol Sci. 2024;25(8):4521. https:\/\/doi.org\/10.3390\/ijms25084521.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1407_CR45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1167\/iovs.64.7.39","volume":"64","author":"S Drag","year":"2023","unstructured":"Drag S, Dotiwala F, Upadhyay AK. Gene therapy for retinal degenerative diseases: progress, challenges, and future directions. Invest Ophthalmol Vis Sci. 2023;64(7):39\u201339.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"1407_CR46","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.4103\/IJO.IJO_2902_23","volume":"72","author":"A Khaparde","year":"2024","unstructured":"Khaparde A, Mathias GP, Poornachandra B, Thirumalesh MB, Shetty R, Ghosh A. Gene therapy for retinal diseases: from genetics to treatment. Indian J Ophthalmol. 2024;72(8):1091\u2013101. https:\/\/doi.org\/10.4103\/IJO.IJO_2902_23. (Epub 2024 Jul 29).","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"1407_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/biom11081179","volume":"11","author":"E Piotter","year":"2021","unstructured":"Piotter E, McClements ME, MacLaren RE. Therapy approaches for Stargardt disease. Biomolecules. 2021;11(8):1179. https:\/\/doi.org\/10.3390\/biom11081179.","journal-title":"Biomolecules"},{"issue":"1","key":"1407_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13816810.2021.1966053","volume":"43","author":"D Huang","year":"2022","unstructured":"Huang D, Heath Jeffery RC, Aung-Htut MT, McLenachan S, Fletcher S, Wilton SD, et al. Stargardt disease and progress in therapeutic strategies. Ophthalmic Genet. 2022;43(1):1\u201326. https:\/\/doi.org\/10.1080\/13816810.2021.1966053. (Epub 2021 Aug 29).","journal-title":"Ophthalmic Genet"},{"issue":"1\u20132","key":"1407_CR49","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/hum.2019.220","volume":"31","author":"P Tornabene","year":"2020","unstructured":"Tornabene P, Trapani I. Can adeno-associated viral vectors deliver effectively large genes? Hum Gene Ther. 2020;31(1\u20132):47\u201356.","journal-title":"Hum Gene Ther"},{"issue":"6","key":"1407_CR50","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1167\/iovs.13-11871","volume":"54","author":"K Binley","year":"2013","unstructured":"Binley K, Widdowson P, Loader J, Kelleher M, Iqball S, Ferrige G, et al. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Investig Ophthalmol Vis Sci. 2013;54(6):4061\u201371. https:\/\/doi.org\/10.1167\/iovs.13-11871.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"2","key":"1407_CR51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/emmm.201302948","volume":"6","author":"I Trapani","year":"2014","unstructured":"Trapani I, Colella P, Sommella A, Iodice C, Cesi G, de Simone S, et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med. 2014;6(2):194\u2013211. https:\/\/doi.org\/10.1002\/emmm.201302948. (Epub 2013 Dec 15).","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1407_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/10430340360464697","volume":"14","author":"SJ Reich","year":"2003","unstructured":"Reich SJ, Auricchio A, Hildinger M, Glover E, Maguire AM, Wilson JM, et al. Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum Gene Ther. 2003;14(1):37\u201344. https:\/\/doi.org\/10.1089\/10430340360464697.","journal-title":"Hum Gene Ther"},{"issue":"12","key":"1407_CR53","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1073\/pnas.97.12.6716","volume":"97","author":"Z Yan","year":"2000","unstructured":"Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA. 2000;97(12):6716\u201321. https:\/\/doi.org\/10.1073\/pnas.97.12.6716.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1407_CR54","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.mt.6300322","volume":"16","author":"A Ghosh","year":"2008","unstructured":"Ghosh A, Yue Y, Lai Y, Duan D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther. 2008;16(1):124\u201330. https:\/\/doi.org\/10.1038\/sj.mt.6300322. (Epub 2007 Nov 6).","journal-title":"Mol Ther"},{"issue":"1","key":"1407_CR55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/hum.2010.122","volume":"22","author":"A Ghosh","year":"2011","unstructured":"Ghosh A, Yue Y, Duan D. Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences. Hum Gene Ther. 2011;22(1):77\u201383. https:\/\/doi.org\/10.1089\/hum.2010.122. (Epub 2010 Dec 12).","journal-title":"Hum Gene Ther"},{"issue":"5","key":"1407_CR56","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1089\/hum.2018.156","volume":"30","author":"ME McClements","year":"2019","unstructured":"McClements ME, Barnard AR, Singh MS, Charbel Issa P, Jiang Z, Radu RA, et al. An AAV dual vector strategy ameliorates the Stargardt phenotype in adult Abca4-\/- mice. Hum Gene Ther. 2019;30(5):590\u2013600. https:\/\/doi.org\/10.1089\/hum.2018.156. (Epub 2018 Dec 24).","journal-title":"Hum Gene Ther"},{"issue":"23","key":"1407_CR57","doi-asserted-by":"publisher","first-page":"6811","DOI":"10.1093\/hmg\/ddv386","volume":"24","author":"I Trapani","year":"2015","unstructured":"Trapani I, Toriello E, de Simone S, Colella P, Iodice C, Polishchuk EV, et al. Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease. Hum Mol Genet. 2015;24(23):6811\u201325. https:\/\/doi.org\/10.1093\/hmg\/ddv386. (Epub 2015 Sep 29).","journal-title":"Hum Mol Genet"},{"issue":"11","key":"1407_CR58","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1089\/hum.2019.132","volume":"30","author":"FM Dyka","year":"2019","unstructured":"Dyka FM, Molday LL, Chiodo VA, Molday RS, Hauswirth WW. Dual ABCA4-AAV vector treatment reduces pathogenic retinal A2E accumulation in a mouse model of autosomal recessive Stargardt disease. Hum Gene Ther. 2019;30(11):1361\u201370. https:\/\/doi.org\/10.1089\/hum.2019.132. (Epub 2019 Sep 30).","journal-title":"Hum Gene Ther"},{"issue":"13","key":"1407_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt9354","volume":"11","author":"R Ferla","year":"2025","unstructured":"Ferla R, Pugni E, Lupo M, Tiberi P, Fioretto F, Perota A, et al. Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models. Sci Adv. 2025;11(13):eadt9354. https:\/\/doi.org\/10.1126\/sciadv.adt9354. (Epub 2025 Mar 26).","journal-title":"Sci Adv"},{"issue":"9","key":"1407_CR60","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1172\/JCI64833","volume":"122","author":"Z Han","year":"2012","unstructured":"Han Z, Conley SM, Makkia RS, Cooper MJ, Naash MI. DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. J Clin Invest. 2012;122(9):3221\u20136. https:\/\/doi.org\/10.1172\/JCI64833. (Epub 2012 Aug 13).","journal-title":"J Clin Invest"},{"issue":"10","key":"1407_CR61","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/13543784.2020.1804853","volume":"29","author":"K Xue","year":"2020","unstructured":"Xue K, MacLaren RE. Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases. Expert Opin Investig Drugs. 2020;29(10):1163\u201370. https:\/\/doi.org\/10.1080\/13543784.2020.1804853. (Epub 2020 Sep 1).","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"1407_CR62","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.3390\/ijms22094621","volume":"22","author":"TZ Tomkiewicz","year":"2021","unstructured":"Tomkiewicz TZ, Su\u00e1rez-Herrera N, Cremers FPM, Collin RWJ, Garanto A. Antisense oligonucleotide-based rescue of aberrant splicing defects caused by 15 pathogenic variants in ABCA4. Int J Mol Sci. 2021;22(9):4621. https:\/\/doi.org\/10.3390\/ijms22094621.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1407_CR63","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ajhg.2018.02.008","volume":"102","author":"S Albert","year":"2018","unstructured":"Albert S, Garanto A, Sangermano R, Khan M, Bax NM, Hoyng CB, et al. Identification and rescue of splice defects caused by two neighboring deep-intronic ABCA4 mutations underlying Stargardt disease. Am J Hum Genet. 2018;102(4):517\u201327. https:\/\/doi.org\/10.1016\/j.ajhg.2018.02.008. (Epub 2018 Mar 8).","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1407_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/genes10060452","volume":"10","author":"A Garanto","year":"2019","unstructured":"Garanto A, Duijkers L, Tomkiewicz TZ, Collin RWJ. Antisense oligonucleotide screening to optimize the rescue of the splicing defect caused by the recurrent deep-intronic ABCA4 variant c.4539+2001G>A in Stargardt disease. Genes (Basel). 2019;10(6):452. https:\/\/doi.org\/10.3390\/genes10060452.","journal-title":"Genes (Basel)"},{"issue":"1","key":"1407_CR65","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ymthe.2019.09.010","volume":"28","author":"D Sun","year":"2020","unstructured":"Sun D, Schur RM, Sears AE, Gao SQ, Vaidya A, Sun W, et al. Non-viral gene therapy for Stargardt disease with ECO\/pRHO-ABCA4 self-assembled nanoparticles. Mol Ther. 2020;28(1):293\u2013303. https:\/\/doi.org\/10.1016\/j.ymthe.2019.09.010. (Epub 2019 Sep 12).","journal-title":"Mol Ther"},{"key":"1407_CR66","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jconrel.2020.12.010","volume":"330","author":"D Sun","year":"2021","unstructured":"Sun D, Sun W, Gao SQ, Wei C, Naderi A, Schilb AL, et al. Formulation and efficacy of ECO\/pRHO-ABCA4-SV40 nanoparticles for nonviral gene therapy of Stargardt disease in a mouse model. J Control Release. 2021;330:329\u201340. https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.010. (Epub 2020 Dec 21).","journal-title":"J Control Release"},{"issue":"29","key":"1407_CR67","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.omtn.2022.08.026","volume":"24","author":"D Sun","year":"2022","unstructured":"Sun D, Sun W, Gao SQ, Lehrer J, Naderi A, Wei C, et al. Effective gene therapy of Stargardt disease with PEG-ECO\/pGRK1-ABCA4-S\/MAR nanoparticles. Mol Ther Nucleic Acids. 2022;24(29):823\u201335. https:\/\/doi.org\/10.1016\/j.omtn.2022.08.026.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"32","key":"1407_CR68","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.omtn.2023.02.032","volume":"3","author":"L Siles","year":"2023","unstructured":"Siles L, Ruiz-Nogales S, Navin\u00e9s-Ferrer A, M\u00e9ndez-Vendrell P, Pomares E. Efficient correction of ABCA4 variants by CRISPR-Cas9 in hiPSCs derived from Stargardt disease patients. Mol Ther Nucleic Acids. 2023;3(32):64\u201379. https:\/\/doi.org\/10.1016\/j.omtn.2023.02.032.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"17","key":"1407_CR69","doi-asserted-by":"publisher","first-page":"251584142513205","DOI":"10.1177\/25158414251320592","volume":"23","author":"E Marks","year":"2025","unstructured":"Marks E, Anugu A, Bisiani J, Pentyala S. Stem cell therapy as treatment for Stargardt disease. Ther Adv Ophthalmol. 2025;23(17):25158414251320590. https:\/\/doi.org\/10.1177\/25158414251320592.","journal-title":"Ther Adv Ophthalmol"},{"issue":"1","key":"1407_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01134-4","volume":"7","author":"DM Hoang","year":"2022","unstructured":"Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7(1):272. https:\/\/doi.org\/10.1038\/s41392-022-01134-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"9967","key":"1407_CR71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","volume":"385","author":"SD Schwartz","year":"2015","unstructured":"Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt\u2019s macular dystrophy: follow-up of two open-label phase 1\/2 studies. Lancet. 2015;385(9967):509\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(14)61376-3. (Epub 2014 Oct 15).","journal-title":"Lancet"},{"issue":"6","key":"1407_CR72","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/bjophthalmol-2020-316225","volume":"105","author":"Y Sung","year":"2021","unstructured":"Sung Y, Lee MJ, Choi J, Jung SY, Chong SY, Sung JH, et al. Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients. Br J Ophthalmol. 2021;105(6):829\u201337. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316225. (Epub 2020 Jul 29).","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"1407_CR73","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/IAE.0000000000003655","volume":"43","author":"RA Brant Fernandes","year":"2023","unstructured":"Brant Fernandes RA, Lojudice FH, Zago Ribeiro L, Santos da Cruz NF, Polizelli MU, Cristovam PC, et al. Transplantation of subretinal stem cell-derived retinal pigment epithelium for Stargardt disease: a phase I clinical trial. Retina. 2023;43(2):263\u201374. https:\/\/doi.org\/10.1097\/IAE.0000000000003655.","journal-title":"Retina"},{"issue":"9","key":"1407_CR74","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13100","volume":"54","author":"SY Li","year":"2021","unstructured":"Li SY, Liu Y, Wang L, Wang F, Zhao TT, Li QY, et al. A phase I clinical trial of human embryonic stem cell-derived retinal pigment epithelial cells for early-stage Stargardt macular degeneration: 5-years\u2019 follow-up. Cell Prolif. 2021;54(9):e13100. https:\/\/doi.org\/10.1111\/cpr.13100. (Epub 2021 Aug 4).","journal-title":"Cell Prolif"},{"issue":"6","key":"1407_CR75","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1089\/cell.2018.0045","volume":"20","author":"A Oner","year":"2018","unstructured":"Oner A, Gonen ZB, Sevim DG, Smim Kahraman N, Unlu M. Suprachoroidal adipose tissue-derived mesenchymal stem cell implantation in patients with dry-type age-related macular degeneration and Stargardt\u2019s macular dystrophy: 6-month follow-up results of a Phase 2 study. Cell Reprogram. 2018;20(6):329\u201336. https:\/\/doi.org\/10.1089\/cell.2018.0045.","journal-title":"Cell Reprogram"},{"issue":"2","key":"1407_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/medicines8020010","volume":"8","author":"JN Weiss","year":"2021","unstructured":"Weiss JN, Levy S. Stem cell ophthalmology treatment study (SCOTS): bone marrow-derived stem cells in the treatment of Stargardt disease. Medicines (Basel). 2021;8(2):10. https:\/\/doi.org\/10.3390\/medicines8020010.","journal-title":"Medicines (Basel)"},{"issue":"6","key":"1407_CR77","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2023.12.028","volume":"131","author":"MS Humayun","year":"2024","unstructured":"Humayun MS, Clegg DO, Dayan MS, Kashani AH, Rahhal FM, Avery RL, et al. Long-term follow-up of a Phase 1\/2a clinical trial of a stem cell-derived bioengineered retinal pigment epithelium implant for geographic atrophy. Ophthalmology. 2024;131(6):682\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2023.12.028. (Epub 2023 Dec 30).","journal-title":"Ophthalmology"},{"issue":"9","key":"1407_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02955-3","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang Y, Tang Z, Gu P. Stem\/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials. Cell Death Dis. 2020;11(9):793. https:\/\/doi.org\/10.1038\/s41419-020-02955-3.","journal-title":"Cell Death Dis"},{"key":"1407_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2025.1646156","volume":"19","author":"J Yang","year":"2025","unstructured":"Yang J, Kuppermann BD, Liao D, Mehta MC, Hsiang C, Menges S, et al. Retinal progenitor cells (jCell) for retinitis pigmentosa. Front Cell Neurosci. 2025;19:1646156. https:\/\/doi.org\/10.3389\/fncel.2025.1646156.","journal-title":"Front Cell Neurosci"},{"issue":"8","key":"1407_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/biom15081167","volume":"15","author":"Q Chen","year":"2025","unstructured":"Chen Q, Zhang T, Chen Z, Zeng J, O\u2019Connor A, Zhu M, et al. Retinal pigment epithelium transplantation in retinal disease: clinical trial development, challenges, and future directions. Biomolecules. 2025;15(8):1167. https:\/\/doi.org\/10.3390\/biom15081167.","journal-title":"Biomolecules"},{"issue":"5","key":"1407_CR81","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.stemcr.2015.04.005","volume":"4","author":"WK Song","year":"2015","unstructured":"Song WK, Park KM, Kim HJ, Lee JH, Choi J, Chong SY, et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Rep. 2015;4(5):860\u201372. https:\/\/doi.org\/10.1016\/j.stemcr.2015.04.005. (Epub 2015 Apr 30).","journal-title":"Stem Cell Rep"},{"key":"1407_CR82","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.ophtha.2018.04.037","volume":"125","author":"MS Mehat","year":"2018","unstructured":"Mehat MS, et al. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration. Ophthalmology. 2018;125:1765\u201375. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.037.","journal-title":"Ophthalmology"},{"issue":"3","key":"1407_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101582","volume":"3","author":"R Sharma","year":"2022","unstructured":"Sharma R, Bose D, Montford J, Ortolan D, Bharti K. Triphasic developmentally guided protocol to generate retinal pigment epithelium from induced pluripotent stem cells. STAR Protoc. 2022;3(3):101582. https:\/\/doi.org\/10.1016\/j.xpro.2022.101582.","journal-title":"STAR Protoc"},{"key":"1407_CR84","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2022.02.025","volume":"182","author":"Y Fang","year":"2022","unstructured":"Fang Y, Taubitz T, Tschulakow AV, Heiduschka P, Szewczyk G, Burnet M, et al. Removal of RPE lipofuscin results in rescue from retinal degeneration in a mouse model of advanced Stargardt Disease: role of reactive oxygen species. Free Radic Biol Med. 2022;182:132\u201349. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.02.025. (Epub 2022 Feb 25).","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"1407_CR85","doi-asserted-by":"publisher","DOI":"10.1096\/fba.2025-00173","volume":"7","author":"R Radhakrishnan","year":"2025","unstructured":"Radhakrishnan R, Leung M, Yochim D, Roehrich H, McPherson SW, Lobo GP. Rescue of the Stargardt disease phenotype in Abca4 knockout mice through dietary modulation of the vitamin A receptor RBPR2. FASEB Bioadv. 2025;7(8):e70044. https:\/\/doi.org\/10.1096\/fba.2025-00173.","journal-title":"FASEB Bioadv"},{"key":"1407_CR86","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.preteyeres.2018.02.002","volume":"65","author":"MT Pardue","year":"2018","unstructured":"Pardue MT, Allen RS. Neuroprotective strategies for retinal disease. Prog Retin Eye Res. 2018;65:50\u201376. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.02.002.","journal-title":"Prog Retin Eye Res"},{"issue":"9","key":"1407_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/biom15091286","volume":"15","author":"PL Grenga","year":"2025","unstructured":"Grenga PL, Ciancimino C, Meduri A, Fragiotta S. Optogenetics: a novel therapeutic avenue for age-related macular degeneration. Biomolecules. 2025;15(9):1286. https:\/\/doi.org\/10.3390\/biom15091286.","journal-title":"Biomolecules"},{"issue":"5","key":"1407_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1243","volume":"13","author":"TT Gao","year":"2023","unstructured":"Gao TT, Oh TJ, Mehta K, Huang YA, Camp T, Fan H, et al. The clinical potential of optogenetic interrogation of pathogenesis. Clin Transl Med. 2023;13(5):e1243. https:\/\/doi.org\/10.1002\/ctm2.1243.","journal-title":"Clin Transl Med"},{"key":"1407_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103430","volume":"87","author":"BL Lam","year":"2025","unstructured":"Lam BL, Zak V, Gonzalez VH, Gregori NZ, Chavala SH, Batabyal S, et al. Safety and efficacy of MCO-010 optogenetic therapy in patients with Stargardt disease in USA (STARLIGHT): an open-label multi-center Ph2 trial. EClinicalMedicine. 2025;87:103430. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103430.","journal-title":"EClinicalMedicine"},{"issue":"10","key":"1407_CR90","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1089\/jop.2024.0084","volume":"40","author":"A Dibas","year":"2024","unstructured":"Dibas A, Batabyal S, Kim S, Carlson M, Mohanty S, Sharif NA. Efficacy of intravitreal Multi-Characteristic Opsin (MCO-010) optogenetic gene therapy in a mouse model of Leber Congenital Amaurosis. J Ocul Pharmacol Ther. 2024;40(10):702\u20138. https:\/\/doi.org\/10.1089\/jop.2024.0084. (Epub 2024 Oct 23).","journal-title":"J Ocul Pharmacol Ther"},{"key":"1407_CR91","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40259-021-00468-9","volume":"35","author":"C Vignal-Clermont","year":"2021","unstructured":"Vignal-Clermont C, Girmens JF, Audo I, et al. Safety of intravitreal gene therapy for treatment of subjects with Leber hereditary optic neuropathy due to mutations in the mitochondrial ND4 gene: the REVEAL study. BioDrugs. 2021;35:201\u201314. https:\/\/doi.org\/10.1007\/s40259-021-00468-9.","journal-title":"BioDrugs"},{"key":"1407_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2016.11","author":"D Marangoni","year":"2016","unstructured":"Marangoni D, Bush RA, Zeng Y, et al. Ocular and systemic safety of a recombinant AAV8 vector for X-linked retinoschisis gene therapy: GLP studies in rabbits and Rs1-KO mice. Mol Ther Methods Clin Dev. 2016. https:\/\/doi.org\/10.1038\/mtm.2016.11.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1407_CR93","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.ymthe.2023.03.035","volume":"31","author":"NR McGrady","year":"2023","unstructured":"McGrady NR, Boal AM, Risner ML, Taiel M, Sahel JA, Calkins DJ. Ocular stress enhances contralateral transfer of lenadogene nolparvovec gene therapy through astrocyte networks. Mol Ther. 2023;31:2005\u201313. https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.035.","journal-title":"Mol Ther"},{"key":"1407_CR94","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.omtm.2021.09.013","volume":"23","author":"DJ Calkins","year":"2021","unstructured":"Calkins DJ, Yu-Wai-Man P, Newman NJ, et al. Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates. Mol Ther. 2021;23:307\u201318. https:\/\/doi.org\/10.1016\/j.omtm.2021.09.013.","journal-title":"Mol Ther"},{"issue":"12","key":"1407_CR95","doi-asserted-by":"publisher","first-page":"7274","DOI":"10.1167\/iovs.15-17371","volume":"56","author":"T Duncker","year":"2015","unstructured":"Duncker T, Stein GE, Lee W, Tsang SH, Zernant J, Bearelly S, et al. Quantitative fundus autofluorescence and optical coherence tomography in ABCA4 carriers. Invest Ophthalmol Vis Sci. 2015;56(12):7274\u201385. https:\/\/doi.org\/10.1167\/iovs.15-17371.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1407_CR96","doi-asserted-by":"publisher","DOI":"10.12688\/openreseurope.13872.3","volume":"1","author":"PPA Dhooge","year":"2022","unstructured":"Dhooge PPA, M\u00f6ller PT, Boon CJF, Lotery AJ, Herrmann P, Battaglia Parodi M, et al. The STArgardt Remofuscin Treatment Trial (STARTT): design and baseline characteristics of enrolled Stargardt patients. Open Res Eur. 2022;1:96. https:\/\/doi.org\/10.12688\/openreseurope.13872.3.","journal-title":"Open Res Eur"},{"issue":"2","key":"1407_CR97","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.12.2.1","volume":"12","author":"PPA Dhooge","year":"2023","unstructured":"Dhooge PPA, M\u00f6ller PT, Meland N, Stingl K, Boon CJF, Lotery AJ, et al. Repeatability of quantitative autofluorescence imaging in a multicenter study involving patients with recessive Stargardt Disease 1. Transl Vis Sci Technol. 2023;12(2):1. https:\/\/doi.org\/10.1167\/tvst.12.2.1.","journal-title":"Transl Vis Sci Technol"},{"issue":"3","key":"1407_CR98","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.14.3.16","volume":"14","author":"I Mihalek","year":"2025","unstructured":"Mihalek I, De Bruyn H, Glavan T, Lancos AM, Ciolfi CM, Malendowicz K, et al. Quantifying the progression of Stargardt disease in double-null ABCA4 carriers using fundus autofluorescence imaging. Transl Vis Sci Technol. 2025;14(3):16. https:\/\/doi.org\/10.1167\/tvst.14.3.16.","journal-title":"Transl Vis Sci Technol"},{"issue":"9","key":"1407_CR99","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00417-015-3254-1","volume":"254","author":"A Sodi","year":"2016","unstructured":"Sodi A, Mucciolo DP, Cipollini F, Murro V, Caporossi O, Virgili G, et al. En face OCT in Stargardt disease. Graefes Arch Clin Exp Ophthalmol. 2016;254(9):1669\u201379. https:\/\/doi.org\/10.1007\/s00417-015-3254-1. (Epub 2016 Jan 7).","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"1407_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170343","volume":"12","author":"R Mastropasqua","year":"2017","unstructured":"Mastropasqua R, Toto L, Borrelli E, Di Antonio L, Mattei PA, Senatore A, et al. Optical coherence tomography angiography findings in Stargardt disease. PLoS ONE. 2017;12(2):e0170343. https:\/\/doi.org\/10.1371\/journal.pone.0170343.","journal-title":"PLoS ONE"},{"issue":"6","key":"1407_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100581","volume":"4","author":"J Charng","year":"2024","unstructured":"Charng J, Thompson JA, Heath Jeffery RC, Kalantary A, Lamey TM, McLaren TL, et al. Censoring the floor effect in long-term Stargardt disease microperimetry data produces a faster rate of decline. Ophthalmol Sci. 2024;4(6):100581. https:\/\/doi.org\/10.1016\/j.xops.2024.100581.","journal-title":"Ophthalmol Sci"},{"key":"1407_CR102","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ajo.2023.05.014","volume":"253","author":"M Pfau","year":"2023","unstructured":"Pfau M, Huryn LA, Boyle MP, Cukras CA, Zein WM, Turriff A, et al. Natural history of visual dysfunction in ABCA4 retinopathy and its genetic correlates. Am J Ophthalmol. 2023;253:224\u201332. https:\/\/doi.org\/10.1016\/j.ajo.2023.05.014. (Epub 2023 May 20).","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1407_CR103","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1167\/iovs.11-8415","volume":"53","author":"AV Cideciyan","year":"2012","unstructured":"Cideciyan AV, Swider M, Aleman TS, Feuer WJ, Schwartz SB, Russell RC, et al. Macular function in macular degenerations: repeatability of microperimetry as a potential outcome measure for ABCA4-associated retinopathy trials. Investig Ophthalmol Vis Sci. 2012;53(2):841\u201352. https:\/\/doi.org\/10.1167\/iovs.11-8415.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"3","key":"1407_CR104","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3109\/13816810.2011.565397","volume":"32","author":"TR Burke","year":"2011","unstructured":"Burke TR, Tsang SH. Allelic and phenotypic heterogeneity in ABCA4 mutations. Ophthalmic Genet. 2011;32(3):165\u201374. https:\/\/doi.org\/10.3109\/13816810.2011.565397. (Epub 2011 Apr 21).","journal-title":"Ophthalmic Genet"},{"issue":"1","key":"1407_CR105","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1044","volume":"8","author":"JC Zenteno","year":"2020","unstructured":"Zenteno JC, Garc\u00eda-Monta\u00f1o LA, Cruz-Aguilar M, Ronquillo J, Rodas-Serrano A, Aguilar-Castul L, et al. Extensive genic and allelic heterogeneity underlying inherited retinal dystrophies in Mexican patients molecularly analyzed by next-generation sequencing. Mol Genet Genomic Med. 2020;8(1):mgg3.1044. https:\/\/doi.org\/10.1002\/mgg3.1044. (Epub 2019 Nov 17).","journal-title":"Mol Genet Genomic Med"},{"issue":"2","key":"1407_CR106","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.gendis.2014.09.002","volume":"1","author":"S Lam","year":"2014","unstructured":"Lam S, Cao H, Wu J, Duan R, Hu J. Highly efficient retinal gene delivery with helper-dependent adenoviral vectors. Genes Dis. 2014;1(2):227\u201337. https:\/\/doi.org\/10.1016\/j.gendis.2014.09.002.","journal-title":"Genes Dis"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01407-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01407-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01407-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:23:22Z","timestamp":1782739402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01407-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":106,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01407-z","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Srikanta Kumar Padhy, Deepika C Parameswarappa, Dhanashree Ratra, and Goura Chattannavar have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.\u00a0Therefore, ethical approval and informed consent were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}